Evoke Pharma Inc.

3.04+0.1500+5.19%Vol 290.31K1Y Perf -83.04%
Jun 24th, 2022 16:00 DELAYED
BID2.89 ASK3.28
Open2.98 Previous Close2.89
Pre-Market- After-Market3.02
 - -  -0.02 -0.66%
Target Price
10.00 
Analyst Rating
— 0.00
Potential %
228.95 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     45.91
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
5.97 
Earnings Rating
Neutral
Market Cap10.16M 
Earnings Date
11th Aug 2022
Alpha-0.01 Standard Deviation0.27
Beta0.78 

Today's Price Range

2.943.35

52W Range

2.0318.96

5 Year PE Ratio Range

-2.40-3.80

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
-5.88%
1 Month
-1.30%
3 Months
-50.21%
6 Months
-59.79%
1 Year
-83.04%
3 Years
-54.87%
5 Years
-90.29%
10 Years
-

TickerPriceChg.Chg.%
EVOK3.040.15005.19
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
6.00
6.70
0.72
2.59
-15.20
Leverage Ratio 3.00
ProfitabilityValueIndustryS&P 500US Markets
85.30
-390.90
-390.90
-
-
RevenueValueIndustryS&P 500US Markets
1.95M
6.99
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.07-
Q03 2021--0.06-
Q02 2021--0.07-
Q01 2021-0.06-0.08-33.33
Q04 2020-0.04-0.09-125.00
Q03 2020-0.10-0.0820.00
Q02 2020-0.08-0.28-250.00
Q01 2020-0.05-0.07-40.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.040.00-
9/2021 QR-0.020.00-
12/2021 FY-0.120.00-
12/2021 FY-0.120.00-
Next Report Date11th Aug 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume290.31K
Shares Outstanding3.34K
Shares Float196.21K
Trades Count1.91K
Dollar Volume918.89K
Avg. Volume2.85M
Avg. Weekly Volume500.10K
Avg. Monthly Volume2.50M
Avg. Quarterly Volume5.56M

Evoke Pharma Inc. (NASDAQ: EVOK) stock closed at 3.04 per share at the end of the most recent trading day (a 5.19% change compared to the prior day closing price) with a volume of 290.31K shares and market capitalization of 10.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 4 people. Evoke Pharma Inc. CEO is David A. Gonyer.

The one-year performance of Evoke Pharma Inc. stock is -83.04%, while year-to-date (YTD) performance is -53.94%. EVOK stock has a five-year performance of -90.29%. Its 52-week range is between 2.03 and 18.96, which gives EVOK stock a 52-week price range ratio of 5.97%

Evoke Pharma Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 4.03, a price-to-sale (PS) ratio of 0.30, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -59.50%, a ROC of -77.11% and a ROE of -174.13%. The company’s profit margin is -%, its EBITDA margin is -390.90%, and its revenue ttm is $1.95 Million , which makes it $6.99 revenue per share.

Of the last four earnings reports from Evoke Pharma Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Evoke Pharma Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Evoke Pharma Inc. is (0), with a target price of $10, which is +228.95% compared to the current price. The earnings rating for Evoke Pharma Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evoke Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evoke Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.13, ATR14 : 0.35, CCI20 : 83.15, Chaikin Money Flow : -0.48, MACD : 0.42, Money Flow Index : 98.71, ROC : 31.03, RSI : 55.11, STOCH (14,3) : 66.01, STOCH RSI : 0.32, UO : 46.80, Williams %R : -33.99), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evoke Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Strong Buy
1.00

Evoke Pharma Inc.

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

CEO: David A. Gonyer

Telephone: +1 858 345-1494

Address: 420 Stevens Avenue, Solana Beach 92075, CA, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

59%41%

Bearish Bullish

57%43%

News

Stocktwits